GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioArctic AB (OSTO:BIOA B) » Definitions » Short Interest

BioArctic AB (OSTO:BIOA B) Short Interest


View and export this data going back to 2017. Start your Free Trial

What is BioArctic AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of BioArctic AB's Short Interest

For the Biotechnology subindustry, BioArctic AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioArctic AB's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioArctic AB's Short Interest distribution charts can be found below:

* The bar in red indicates where BioArctic AB's Short Interest falls into.


BioArctic AB (OSTO:BIOA B) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioArctic AB (OSTO:BIOA B) » Definitions » Short Interest
Comparable Companies
OSTO:CAMX OSTO:CALTX OSTO:GENO OSTO:VICO OSTO:EGTX OSTO:HNSA OSTO:IBT B OSTO:FLUO OSTO:BINV OSTO:XSPRAY OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
BRCTF:USA 0RV2:UK B9A:Germany
Address
Warfvinges vag 35, Stockholm, SWE, SE-112 51
Website
https://www.bioarctic.se
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. In addition, the group is also focused on the development of a treatment with a combination of a biodegradable medical device and a drug substance for complete spinal cord injury. Geographically, it derives a majority of its revenue from Asia.

BioArctic AB (OSTO:BIOA B) Headlines

No Headlines